USP17L13: A Drug Target / Disease Biomarker (G100287238)
USP17L13: A Drug Target / Disease Biomarker
USP17L13 is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell adhesion and has been implicated in a number of diseases, including cancer.
One of the most promising aspects of USP17L13 is its potential as a drug target. USP17L13 has been shown to play a role in a variety of processes that are important for cancer progression, including the development of tumors, the growth of cancer cells, and the development of cancer-induced immune evasion.
In addition, USP17L13 has also been shown to be involved in the regulation of cell signaling pathways that are important for cancer growth and progression. For example, studies have shown that USP17L13 can regulate the activity of the TGF-β pathway, a pathway that is involved in the development and maintenance of tissues and organs.
Another promising aspect of USP17L13 is its potential as a biomarker for cancer. Studies have shown that USP17L13 can be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, research has shown that USP17L13 can be used as a marker for cancer progression and recurrence.
In conclusion, USP17L13 is a protein that has the potential to be a drug target for cancer. Its involvement in the regulation of cell adhesion and its role in the TGF-β pathway make it an attractive target for drug development. Furthermore, its potential as a biomarker for cancer makes it an important compound to study further.
Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 13
Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection
The "USP17L13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L13 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1
